Quick Answer
Biofrontera Inc. reported R&D Expense of $3.72 million for fiscal year 2025.
Biofrontera Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.72M | +78.0% |
| 2024 | $2.09M | +2613.0% |
| 2023 | $77.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $854.0K | +27.7% | -1.8% |
| June 30, 2025 | $870.0K | +40.1% | -27.9% |
| March 31, 2025 | $1.21M | +7000.0% | +80.4% |
| September 30, 2024 | $669.0K | +1927.3% | +7.7% |
| June 30, 2024 | $621.0K | +5545.5% | +3552.9% |
| March 31, 2024 | $17.0K | — | -48.5% |
| September 30, 2023 | $33.0K | — | +200.0% |
| June 30, 2023 | $11.0K | — | — |
- Biofrontera Inc. showed an increase of +78.0% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Biofrontera Inc.’s r&d expense has grown by 4729.9% (from $77.0 thousand to $3.72 million).
- The most recent figure is from Biofrontera Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: